OA11307A - Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes - Google Patents
Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes Download PDFInfo
- Publication number
- OA11307A OA11307A OA9900279A OA9900279A OA11307A OA 11307 A OA11307 A OA 11307A OA 9900279 A OA9900279 A OA 9900279A OA 9900279 A OA9900279 A OA 9900279A OA 11307 A OA11307 A OA 11307A
- Authority
- OA
- OAPI
- Prior art keywords
- dmf
- methyl
- drug delivery
- therapeutic composition
- inclusive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/874,425 US5935597A (en) | 1995-12-15 | 1997-06-13 | Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11307A true OA11307A (en) | 2003-10-24 |
Family
ID=25363728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA9900279A OA11307A (en) | 1997-06-13 | 1999-12-10 | Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1011567A1 (no) |
| JP (1) | JP4531141B2 (no) |
| KR (1) | KR20010013709A (no) |
| CN (1) | CN1260703A (no) |
| AP (1) | AP1629A (no) |
| AR (1) | AR012970A1 (no) |
| AU (1) | AU7831598A (no) |
| BG (1) | BG103997A (no) |
| BR (1) | BR9810095A (no) |
| CA (1) | CA2295176A1 (no) |
| CZ (1) | CZ298510B6 (no) |
| EA (1) | EA200000011A1 (no) |
| EE (1) | EE9900562A (no) |
| ES (1) | ES2161187B1 (no) |
| FI (1) | FI19992648A7 (no) |
| GB (1) | GB2341319B (no) |
| HU (1) | HUP0003034A2 (no) |
| ID (1) | ID23516A (no) |
| IL (2) | IL133396A0 (no) |
| IS (1) | IS5289A (no) |
| LT (1) | LT4714B (no) |
| LV (1) | LV12490B (no) |
| NO (1) | NO996117L (no) |
| NZ (1) | NZ501669A (no) |
| OA (1) | OA11307A (no) |
| PL (1) | PL196256B1 (no) |
| RO (1) | RO121252B1 (no) |
| SI (1) | SI20191A (no) |
| SK (1) | SK172299A3 (no) |
| TN (1) | TNSN98086A1 (no) |
| TR (1) | TR200000540T2 (no) |
| WO (1) | WO1998056325A1 (no) |
| YU (1) | YU66099A (no) |
| ZA (1) | ZA984649B (no) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060029162A (ko) * | 2003-06-30 | 2006-04-04 | 알자 코포레이션 | 피부 피어싱 미세돌출부를 코팅하는 방법 |
| CN1921829B (zh) * | 2003-12-05 | 2010-05-05 | 纳米比亚医学调查研究有限公司 | 贴片 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE60941B1 (en) * | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4855294A (en) * | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
| US5534260A (en) * | 1989-02-23 | 1996-07-09 | University Of Utah | Percutaneous drug delivery system |
| US5028435A (en) * | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
| US5624912A (en) * | 1991-08-21 | 1997-04-29 | Burcoglu; Arsinur | Method of treating HIV infection and related secondary infections with defibrotide |
| ATE165345T1 (de) * | 1992-02-20 | 1998-05-15 | Merrell Pharma Inc | Sulfonsaeurederivate zur behandlung von viruserkrankungen |
| TR199801066T2 (xx) * | 1995-12-15 | 1998-08-21 | Cryopreservation Technologies Cc | Organ kriyokorumas� ve viral ve bakteryal enfeksiyonlar�n iyile�tirilmesi i�in bile�im. |
-
1998
- 1998-05-29 ZA ZA9804649A patent/ZA984649B/xx unknown
- 1998-06-09 SK SK1722-99A patent/SK172299A3/sk unknown
- 1998-06-09 JP JP50311899A patent/JP4531141B2/ja not_active Expired - Fee Related
- 1998-06-09 ID IDW20000042A patent/ID23516A/id unknown
- 1998-06-09 NZ NZ501669A patent/NZ501669A/en unknown
- 1998-06-09 AU AU78315/98A patent/AU7831598A/en not_active Abandoned
- 1998-06-09 CZ CZ0447399A patent/CZ298510B6/cs not_active IP Right Cessation
- 1998-06-09 CN CN98806085A patent/CN1260703A/zh active Pending
- 1998-06-09 YU YU66099A patent/YU66099A/sh unknown
- 1998-06-09 GB GB9929189A patent/GB2341319B/en not_active Expired - Fee Related
- 1998-06-09 ES ES009950072A patent/ES2161187B1/es not_active Expired - Lifetime
- 1998-06-09 IL IL13339698A patent/IL133396A0/xx active IP Right Grant
- 1998-06-09 AP APAP/P/1999/001708A patent/AP1629A/en active
- 1998-06-09 EE EEP199900562A patent/EE9900562A/xx unknown
- 1998-06-09 EP EP98926488A patent/EP1011567A1/en not_active Withdrawn
- 1998-06-09 EA EA200000011A patent/EA200000011A1/ru unknown
- 1998-06-09 HU HU0003034A patent/HUP0003034A2/hu unknown
- 1998-06-09 CA CA002295176A patent/CA2295176A1/en not_active Abandoned
- 1998-06-09 WO PCT/US1998/011956 patent/WO1998056325A1/en not_active Ceased
- 1998-06-09 BR BR9810095-5A patent/BR9810095A/pt not_active Application Discontinuation
- 1998-06-09 RO RO99-01313A patent/RO121252B1/ro unknown
- 1998-06-09 PL PL338439A patent/PL196256B1/pl unknown
- 1998-06-09 KR KR1019997011724A patent/KR20010013709A/ko not_active Withdrawn
- 1998-06-09 TR TR2000/00540T patent/TR200000540T2/xx unknown
- 1998-06-09 SI SI9820040A patent/SI20191A/sl unknown
- 1998-06-11 AR ARP980102783A patent/AR012970A1/es not_active Application Discontinuation
- 1998-06-12 TN TNTNSN98086A patent/TNSN98086A1/fr unknown
-
1999
- 1999-12-08 IS IS5289A patent/IS5289A/is unknown
- 1999-12-09 FI FI19992648A patent/FI19992648A7/fi unknown
- 1999-12-09 IL IL133396A patent/IL133396A/en not_active IP Right Cessation
- 1999-12-10 OA OA9900279A patent/OA11307A/en unknown
- 1999-12-10 NO NO996117A patent/NO996117L/no not_active Application Discontinuation
- 1999-12-13 BG BG103997A patent/BG103997A/xx unknown
- 1999-12-20 LT LT99-148A patent/LT4714B/lt not_active IP Right Cessation
-
2000
- 2000-02-02 LV LVP-99-182A patent/LV12490B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Soudeyns et al. | Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog | |
| Yamamoto et al. | Human alpha-and beta-interferon but not gamma-suppress the in vitro replication of LAV, HTLV-III, and ARV-2 | |
| Zucker-Franklin et al. | Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA. | |
| Lundgren et al. | Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus | |
| Hammer et al. | Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro | |
| Hostetler et al. | Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine | |
| US5935597A (en) | Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes | |
| Togo et al. | Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus | |
| Carter et al. | Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro | |
| Kimes et al. | Reduction of cerebral glucose utilization by the HIV envelope glycoprotein Gp-120 | |
| Richman | Antiviral therapy of HIV infection | |
| OA11307A (en) | Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes | |
| NO881190L (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 9-(beta-d-deoxyribofuranosyl)-mucleosider. | |
| Harbison et al. | Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages | |
| Geleziunas et al. | Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages | |
| Biagiotti et al. | Abnormalities of in vitro immunoglobulin production in apparently healthy haemophiliacs: relationship with alterations of T cell subsets and with HTLV-III seropositivity | |
| Chokekijchai et al. | In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI | |
| Gupta | Therapy of AIDS and AIDS-related syndromes | |
| Weber et al. | Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study | |
| US5182306A (en) | Use of colchicine for the control of retroviruses | |
| Kalnina et al. | Evaluation of anti-HIV-1 (Retroviridae: Orthoretrovirinae: Lentivirus: Human immunodeficiency virus type 1) activity of 6HP and 3TC in vitro using MT-4 cell line variants with different replicative activity | |
| Nakashima et al. | Effect of HTLV-III on the macromolecular synthesis in HTLV-I carrying cell line, MT-4 | |
| JPH03227925A (ja) | エイズ原因ウィルスに対する抗ウイルス剤 | |
| Fritsch et al. | Anti-retroviral therapy in HIV-1-infected persons: Concepts and strategies | |
| EP0380618A1 (en) | The use of colchicine and related compounds for the manufacture of a medicament for the control of retroviruses |